Uwell Biopharma, Inc. (TPEX:7902)
Taiwan
· Delayed Price · Currency is TWD 46.75
-0.20 (-0.43%)
At close: Apr 28, 2026
Uwell Biopharma Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2018 |
| Cash & Equivalents | 220.31 | 43.4 | 23.09 | 27.71 | 49.76 | 35.69 | Upgrade
|
| Short-Term Investments | - | 4.5 | 63 | - | 18 | - | Upgrade
|
| Cash & Short-Term Investments | 220.31 | 47.9 | 86.09 | 27.71 | 67.76 | 35.69 | Upgrade
|
| Cash Growth | 695.07% | -44.37% | 210.70% | -59.11% | 89.86% | -62.25% | Upgrade
|
| Other Receivables | 0.03 | 0.04 | 0.07 | 0 | 0.02 | 0.82 | Upgrade
|
| Receivables | 0.03 | 0.04 | 0.07 | 0 | 0.02 | 0.82 | Upgrade
|
| Prepaid Expenses | 0.44 | 0.46 | 0.71 | 0.48 | 4.32 | 2.94 | Upgrade
|
| Other Current Assets | 0.02 | 0.09 | 0.05 | 0.27 | 0.06 | 0.18 | Upgrade
|
| Total Current Assets | 220.79 | 48.48 | 86.91 | 28.46 | 72.16 | 39.63 | Upgrade
|
| Property, Plant & Equipment | 16.73 | 19.56 | 25.48 | 26.6 | 33.11 | 38.92 | Upgrade
|
| Other Intangible Assets | 0.02 | 0.04 | 0.09 | 0.23 | 0.43 | 0.42 | Upgrade
|
| Other Long-Term Assets | 8.19 | 8.08 | 6.04 | 5.11 | 0.58 | 0.58 | Upgrade
|
| Total Assets | 245.73 | 76.16 | 118.51 | 60.4 | 106.27 | 79.55 | Upgrade
|
| Accrued Expenses | 12.09 | 5.36 | 4.42 | 5.62 | 5.52 | 4.45 | Upgrade
|
| Current Portion of Leases | 2.57 | 4.25 | 4.14 | 3.4 | 4.19 | 4.04 | Upgrade
|
| Other Current Liabilities | 0.95 | 1.09 | 0.49 | 0.8 | 1.09 | 1.44 | Upgrade
|
| Total Current Liabilities | 15.61 | 10.7 | 9.05 | 9.81 | 10.8 | 9.93 | Upgrade
|
| Long-Term Leases | - | 0.86 | 3.98 | 4.95 | 8.34 | 12.48 | Upgrade
|
| Total Liabilities | 15.61 | 11.56 | 13.03 | 14.76 | 19.15 | 22.42 | Upgrade
|
| Common Stock | 117 | 117 | 117 | 57 | 251.8 | 171.8 | Upgrade
|
| Additional Paid-In Capital | 153.08 | 2.54 | 47.54 | 2.54 | 3.18 | 3.18 | Upgrade
|
| Retained Earnings | -90.3 | -55.3 | -59.43 | -14.26 | -168.23 | -118.23 | Upgrade
|
| Comprehensive Income & Other | 50.35 | 0.38 | 0.38 | 0.37 | 0.37 | 0.38 | Upgrade
|
| Shareholders' Equity | 230.13 | 64.61 | 105.48 | 45.64 | 87.13 | 57.13 | Upgrade
|
| Total Liabilities & Equity | 245.73 | 76.16 | 118.51 | 60.4 | 106.27 | 79.55 | Upgrade
|
| Total Debt | 2.57 | 5.11 | 8.12 | 8.34 | 12.53 | 16.53 | Upgrade
|
| Net Cash (Debt) | 217.73 | 42.79 | 77.98 | 19.37 | 55.23 | 19.16 | Upgrade
|
| Net Cash Growth | 1024.36% | -45.13% | 302.67% | -64.94% | 188.23% | -78.99% | Upgrade
|
| Net Cash Per Share | 1.86 | 0.37 | 0.88 | 0.34 | 2.34 | 0.90 | Upgrade
|
| Filing Date Shares Outstanding | 117 | 117 | 117 | 57 | 29.2 | 21.2 | Upgrade
|
| Total Common Shares Outstanding | 117 | 117 | 117 | 57 | 29.2 | 21.2 | Upgrade
|
| Working Capital | 205.18 | 37.79 | 77.86 | 18.65 | 61.36 | 29.69 | Upgrade
|
| Book Value Per Share | 1.97 | 0.55 | 0.90 | 0.80 | 2.98 | 2.69 | Upgrade
|
| Tangible Book Value | 230.1 | 64.57 | 105.4 | 45.41 | 86.7 | 56.71 | Upgrade
|
| Tangible Book Value Per Share | 1.97 | 0.55 | 0.90 | 0.80 | 2.97 | 2.67 | Upgrade
|
| Machinery | 16.44 | 16.44 | 16.44 | 14.44 | 14.31 | 14.03 | Upgrade
|
| Construction In Progress | 1.11 | - | - | - | 5.79 | 5.79 | Upgrade
|
| Leasehold Improvements | 9.32 | 9.32 | 9.32 | 9.32 | 3.19 | 3.19 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.